Endo receives subpoena on Lidoderm promotion

Share this article:
The US Department of Health and Human Services (HHS) has issued Endo Pharmaceuticals a subpoena regarding the promotion of its post-shingles pain patch Lidoderm. The subpoena requests documents from 1999 to the present related to the company’s knowledge of the use of Lidoderm for off-label uses for the treatment. Although physicians are allowed to prescribe drugs for off-label uses, pharmaceutical companies are not permitted to market drugs for non-approved uses. Endo said it would cooperate with the HHS’ request to provide the materials. “Endo has been and will continue to be firmly committed to promoting Lidoderm and all of Endo’s marketed products responsibly and appropriately within their currently approved indications,” said CEO Peter Lankau. “We have a strong ethics and compliance program. To that end, we routinely conduct extensive training for our employees to reinforce the importance of promotional practices that are within the FDA-approved indication.”
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.